Achieve Life Sciences said the FDA declined to approve its nicotine-dependence drug for adults, representing a regulatory setback that blocks near-term US commercialization. The outcome heightens questions about cytisinicline's path to market and may trigger additional data submissions or trials, financing considerations, and potential licensing deals. The stock could remain volatile until a concrete plan is announced.
ACHV is seeking FDA approval for cytisinicline, targeting 2026 launch. HC Wainwright has initiated coverage with a Buy rating and $12 price target. Cytisinicline shows greater efficacy in smoking cessation compared to existing therapies. Company raised $45 million to support NDA and operational costs. Analysts predict significant stock value growth in the next 12-18 months.
